InnoCare Pharma (688428.SH): Zurletrectinib Tablets Included in 2026 National Medical Insurance Catalog

Zhitong Finance APP News, InnoCare Pharma (688428.SH) announced that the Company's self-developed next-generation TRK inhibitor zurletrectinib tablets (brand name: Yinuoxin) has been included in the new version of the National Reimbursement Drug List (NRDL) for the treatment of adult and adolescent (aged 12 and above) patients with solid tumors harboring NTRK fusion genes. The new version of the NRDL will be officially implemented starting January 1, 2027. The agreement is valid from January 1, 2027 to December 31, 2028.